title: Effect of corticosteroids on phlebitis induced by intravenous infusion of antineoplastic agents in rabbits.
abstract: OBJECTIVE
  Phlebitis caused by intravenous infusion of antineoplastic agents is one of the critical problems when anticancer therapy is prolonged. We have already reported that both rapid infusion and dilution of the injection solution were effective methods for reducing phlebitis caused by vinorelbine (VNR) in rabbits. The aim of this study was to explore other practical methods for preventing phlebitis caused by VNR and doxorubicin (DXR) in a rabbit model. VNR is often used with cisplatin, and dexamethasone (DEX) has been co-administered for prevention of cisplatin-induced nausea. DXR is used with prednisolone (PSL) in the CHOP regimen for the treatment of non-Hodgkin's lymphoma. Therefore, the present study investigated the prevention of phlebitis due to VNR with DEX and that due to DXR with PSL.
  
  
  METHODS
  VNR and DXR were diluted with normal saline to prepare test solutions at concentrations of 0.6 mg/mL and 1.4 mg/mL, respectively. Each test solution was infused into the auricular veins of rabbits. Two days after VNR infusion and three days after DXR infusion, the veins were evaluated histopathologically. The effect of DEX on VNR-induced phlebitis was evaluated by infusion of DEX before or after VNR. The effect of PSL on DXR-induced phlebitis was similarly evaluated by co-infusion of PSL.
  
  
  RESULTS
  The histopathological features of phlebitis caused by the antineoplastic agents differed between VNR and DXR: VNR did not cause the loss of venous endothelial cells, but caused inflammatory cell infiltration, edema, and epidermal degeneration. In contrast, DXR caused the loss of venous endothelial cells and chrondrocyte necrosis. Pre-treatment and post-treatment with DEX significantly decreased VNR-induced phlebitis compared with the control group and pre-treatment was particularly effective. Co-infusion of PSL also significantly decreased phlebitis caused by DXR, but its effect was less marked.
  
  
  CONCLUSIONS
  The present findings suggested that pre-treatment with DEX may be a useful method for preventing phlebitis due to VNR, and that co-infusion of PSL has the potential to prevent phlebitis caused by DXR.
authors.affiliation: Department of Hospital Pharmacy, Kansai Medical University Takii Hospital, 10-15 Fumizono-cho, Moriguchi, Osaka 570-8507, Japan. kohnoe@takii.kmu.ac.jp
authors.forename: Emiko
authors.initials: E
authors.lastname: Kohno
authors.forename: Saori
authors.initials: S
authors.lastname: Murase
authors.forename: Kenji
authors.initials: K
authors.lastname: Matsuyama
authors.forename: Noboru
authors.initials: N
authors.lastname: Okamura
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D007262:Infusions, Intravenous; D008297:Male; D010689:Phlebitis / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D011817:Rabbits; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077235:Vinorelbine
chemical_list: D000305:Adrenal Cortex Hormones; D000970:Antineoplastic Agents; D014747:Vinblastine; D003907:Dexamethasone; D004317:Doxorubicin; D011239:Prednisolone; D000077235:Vinorelbine
references.citation: Lancet. 1956 Apr 21;270(6921):484-5
references.pmid: 13307973
references.citation: Nutrition. 1994 May-Jun;10(3):261-3
references.pmid: 7919680
references.citation: J Surg Res. 1968 Nov;8(11):539-43
references.pmid: 5687385
references.citation: Lung Cancer. 2007 Mar;55(3):337-41
references.pmid: 17126951
references.citation: J Oncol Pharm Pract. 2005 Jun;11(2):79-81
references.pmid: 16460608
references.citation: Nutrition. 1998 Jun;14(6):496-501
references.pmid: 9646289
references.citation: Pharm Weekbl Sci. 1984 Apr 27;6(2):88-90
references.pmid: 6728639
references.citation: Gan To Kagaku Ryoho. 2002 Apr;29(4):633-5
references.pmid: 11977554
references.citation: Oncol Nurs Forum. 1990 May-Jun;17(3):387-9
references.pmid: 2342972
references.citation: Int J Med Sci. 2008 Jul 22;5(4):218-23
references.pmid: 18695742
references.citation: J Toxicol Sci. 1998 Feb;23(1):77-85
references.pmid: 9513923
references.citation: J Chemother. 1997 Aug;9(4):304-8
references.pmid: 9269613
references.citation: Jpn J Clin Oncol. 2004 Apr;34(4):206-9
references.pmid: 15121757
references.citation: J Appl Toxicol. 2004 Nov-Dec;24(6):409-13
references.pmid: 15558643
references.citation: Gan To Kagaku Ryoho. 2009 Jan;36(1):93-6
references.pmid: 19151570